May 25, 2022 / 05:00PM GMT
Matthew Oliver O'Brien - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Good afternoon, everybody. It's Matt O'Brien from Piper's MedTech research team on here with you. Thanks for joining our Annual Diabetes Day conference. We're really excited to have DexCom on with us. From the company is Brice Bobzien, the Senior Vice President of Finance. I think Sean and Matt are kind of in the background as well, listening in.
Format of the call is going to be pretty typical. A bunch of questions from me. This is an interactive session, so please do use the Q&A feature at the bottom of the Zoom, if you have questions, or just e-mail me, and I'm happy to ask those questions on your behalf. It's [email protected].
And with those comments out of the way, let's go ahead and get started. Brice, thanks again for the time here today. Really appreciate you hopping on with us.
Brice Bobzien - DexCom, Inc. - VP of Finance
Of course, Matt, thanks so much for having us. I appreciate the opportunity.
Dexcom Inc at Piper Sandler Ophthalmology and Diabetes Symposium (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot